Engineered botulinum neurotoxin

Patent metadata

Field	Value
Publication number	US-10844362-B2
Application number	US-201916252083-A
Country	US
Kind code	B2
Filing date	Jan 18, 2019
Priority date	May 30, 2012
Publication date	Nov 24, 2020
Grant date	Nov 24, 2020

Abstract

Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; S1201V; or combinations thereof. Specific combination mutations include E1191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S1199Y, or E1191Q and S1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.

First claim

What is claimed:

1. A polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B (B-H c ) that possesses at least 95% amino acid sequence identity to a corresponding domain as found in the amino acid sequence of SEQ ID NO: 4 and furthermore comprises one or more substitution mutations at positions in the corresponding domain of the amino acid sequence of SEQ ID NO: 4, wherein one of the substitution mutations is S1201V, and wherein the one or more substitution mutations produces enhanced binding of the modified B-H c to human SytII as compared to an identical molecule lacking the one or more substitution mutations.

2. The polypeptide of claim 1 , that is a botulinum neurotoxin (BoNT) polypeptide comprising:
a) a protease domain;
b) a protease cleavage site;
c) a translocation domain; and
d) the modified B-H c .

3. The polypeptide of claim 1 , wherein the modified B-H c comprises two substitution mutations.

4. The polypeptide of claim 3 , wherein the two substitution mutations correspond to:
S1201V and Y1183M;
S1201V and V1118M; or
S1201V and E1191M.

5. The polypeptide of claim 1 , wherein the substitution mutation is a non-naturally occurring amino acid.

6. The polypeptide of claim 1 , wherein the modified B-H c is of strain 1.

7. The polypeptide of claim 2 wherein the protease domain, translocation domain, and protease cleavage site are from serotype selected from the group consisting of A, B, C, D, E, F, G, and combinations thereof.

8. The polypeptide of claim 7 , wherein the protease domain, translocation domain, and protease cleavage site are from serotype B, strain 1.

9. The polypeptide of claim 7 , wherein the protease domain, translocation domain, and protease cleavage site are from serotype A, strain 1.

10. A composition comprising a botulinum neurotoxin polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B (B-H c ) that possesses at least 95% amino acid sequence identity to a corresponding domain as found in the amino acid sequence of SEQ ID NO: 4 and furthermore comprises one or more substitution mutations at positions in the corresponding domain of the amino acid sequence of SEQ ID NO: 4, wherein one of the substitution mutations is S1201V, and wherein the one or more substitution mutations produces enhanced binding of the modified B-H c to human SytII as compared to an identical molecule lacking the one or more substitution mutations.

11. The composition of claim 10 , wherein the modified B-H c comprises two substitution mutations.

12. The polypeptide of claim 11 , wherein the two substitution mutations correspond to:
S1201V and Y1183M;
S1201V and V1118M; or
S1201V and E1191M.

13. A chimeric molecule comprising a first portion that is a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc) that possesses at least 95% amino acid sequence identity to a corresponding domain as found in the amino acid sequence of SEQ ID NO: 4 and furthermore comprises one or more substitution mutations at positions in the corresponding domain of the amino acid sequence of SEQ ID NO: 4, wherein one of the substitution mutations is S1201V, linked to a second portion.

14. The chimeric molecule of claim 13 , wherein the first portion and the second portion are linked covalently.

15. The chimeric molecule of claim 13 , wherein the first portion and the second portion are linked non-covalently.

16. The chimeric molecule of claim 13 , wherein the second portion is selected from the group consisting of a small molecule, a nucleic acid, a short polypeptide, and a protein.

17. A composition comprising a chimeric molecule comprising a first portion that is the modified receptor binding domain of Clostridial botulinum serotype B (B-Hc) that possesses at least 95% amino acid sequence identity to a corresponding domain as found in the amino acid sequence of SEQ ID NO: 4 and furthermore comprises one or more substitution mutations at positions in the corresponding domain of the amino acid sequence of SEQ ID NO: 4, wherein one of the substitution mutations is S1201V, linked to a second portion.

18. A kit comprising a composition comprising a botulinum neurotoxin polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B (B-H c ) that possesses at least 95% amino acid sequence identity to a corresponding domain as found in the amino acid sequence of SEQ ID NO: 4 and furthermore comprises one or more substitution mutations at positions in the corresponding domain of the amino acid sequence of SEQ ID NO: 4, wherein one of the substitution mutations is S1201V, and wherein the one or more substitution mutations produces enhanced binding of the modified B-H c to human SytII as compared to an identical molecule lacking the one or more substitution mutations, and directions for therapeutic administration of the composition.

19. A kit comprising a composition comprising a chimeric molecule comprising a first portion that is the modified receptor binding domain of Clostridial botulinum serotype B (B-Hc) that possesses at least 95% amino acid sequence identity to a corresponding domain as found in the amino acid sequence of SEQ ID NO: 4 and furthermore comprises one or more substitution mutations at positions in the corresponding domain of the amino acid sequence of SEQ ID NO: 4, wherein one of the substitution mutations is S1201V, linked to a second portion and directions for administration of the composition.

20. A method for treating a condition in a subject associated with unwanted neuronal activity comprising administering a therapeutically effective amount of the polypeptide of claim 1 .

21. The method of claim 20 , wherein the condition is selected from the group consisting of spasmodic dysphonia, spasmodic torticollis, laryngeal dystonia, oromandibular dysphonia, lingual dystonia, cervical dystonia, focal hand dystonia, blepharospasm, strabismus, hemifacial spasm, eyelid disorder, cerebral palsy, focal spasticity and other voice disorders, spasmodic colitis, neurogenic bladder, anismus, limb spasticity, tics, tremors, bruxism, anal fissure, achalasia, dysphagia and other muscle tone disorders and other disorders characterized by involuntary movements of muscle groups, lacrimation, hyperhydrosis, excessive salivation, excessive gastrointestinal secretions, secretory disorders, pain from muscle spasms, headache pain, and dermatological or aesthetic/cosmetic conditions.

Assignees

• Harvard College
• President And Fellows Of Harvard

Inventors

• Dong Min
• Peng Lisheng
• Stenmark Pål Erik Gustav
• Berntsson Ronnie Per Arne

Classifications

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• C07K14/33 Primary

  from Clostridium (G) · CPC title

• C07K19/00

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title